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Abstract: Though several previous studies reported the in vitro and in vivo antioxidant effect of
kinetin (Kn), details on its action in cisplatin-induced toxicity are still scarce. In this study we
evaluated, for the first time, the effects of kinetin in cisplatin (cp)- induced liver and lymphocyte
toxicity in rats. Wistar male albino rats were divided into nine groups: (i) the control (C), (ii) groups
2,3 and 4, which received 0.25, 0.5 and 1 mg/kg kinetin for 10 days; (iii) the cisplatin (cp) group, which
received a single intraperitoneal injection of CP (7.0 mg/kg); and (iv) groups 6, 7, 8 and 9, which
received, for 10 days, 0.25, 0.5 and 1 mg/kg kinetin or 200 mg/kg vitamin C, respectively, and Cp
on the fourth day. CP-injected rats showed a significant impairment in biochemical, oxidative stress
and inflammatory parameters in hepatic tissue and lymphocytes. PCR showed a profound increase
in caspase-3, and a significant decline in AKT gene expression. Intriguingly, Kn treatment restored
the biochemical, redox status and inflammatory parameters. Hepatic AKT and caspase-3 expression
as well as CD95 levels in lymphocytes were also restored. In conclusion, Kn mitigated oxidative
imbalance, inflammation and apoptosis in CP-induced liver and lymphocyte toxicity; therefore, it can
be considered as a promising therapy.
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1. Introduction

iations.

Cisplatin (CP) is one of the most widely used and effective anti-neoplastic drugs. It
is used to treat a wide variety of cancers, including those that affect the testicles, ovaries,
cervical region, bladder, head and neck, as well as the lung [1]. CP induces many toxicities,
including nephrotoxicity, hepatotoxicity, cardiotoxicity, neurotoxicity and ototoxicity, which
restrict its clinical usage [2–4]. A large number of experimental research papers have
provided evidence of the prevalent toxic side effects associated with CP, most notably
nephrotoxicity [5]. Additionally, it has been shown that hepatotoxicity is a prominent
dose-limiting adverse effect of CP-based chemotherapy [6,7]. Furthermore, accumulating
evidence points to cisplatin’s ability to induce genotoxicity/DNA damage in bone marrow
and human lymphocytes [8]. The production of reactive oxygen species (ROS), including
superoxide anions and hydroxyl radicals, which leads to an increase in lipid peroxidation
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and cell damage, is what drives the toxicity that is induced by CP. Likewise, apoptosis
and cell arrest are events resulting from an excess of reactive oxygen species in cancer
cells as well as non-target normal cells [9,10]. Although the increased oxidative stress and
inflammation are the main mechanisms involved in toxicity induced by CP, other molecular
pathways have yet to be revealed.
Recently, considerable focus has been placed on the protective function that naturally
occurring compounds with antioxidants and anti-inflammatory characteristics provide,
as well as the mechanism by which they exert their effects. Cytokinins (CKs) are natural
products that have lately come to the forefront of attention. These natural compounds have
a variety of therapeutic and pharmacological effects [11]. Researchers were prompted to
investigate the process of CK production at the nucleic acid level due to the prevalence
of CKs in DNA and cell extracts [12]. The small-molecule adenosine N6-furfuryladenine
(N6FFA: kinetin) is commonly used by the plant community as a low-priced proxy for the
natural cytokinins (CKs) in plant tissue culture and other experiments relevant to plant
growth and development [11,13].
A long time ago, Kn was thought to be an artificial product of DNA rearrangement [14],
but it was then discovered in extracts from Casuarina equisetifolia root nodules infected
with the bacteria Frankia in 1996, which was the first evidence of its natural occurrence [15].
In addition, and in the same year, Barciszewski et al., discovered kinetin in plant cell extracts
(0.1 ng/g dried material), DNA extracted from human fibroblasts cultivated in vitro and
commercially available calf thymus DNA [16].
Kinetin was found in the endosperm liquid of fresh young coconut fruits, plant cell
extracts, human urine and various other biological extracts [11].
Furthermore, the free radical scavenging activity of kn was investigated in vitro in
inactivated platelets, and the findings show that Kn inhibited the generation of hydroxyl
radicals in a dose-dependent manner, as well as exerting antithrombotic action in three
in vivo models [17]. Besides its antioxidant activity, Othman et al., (2021) have provided
evidence of the anti-inflammatory action of kinetin, suggesting that it can be used as a
potential therapeutic agent against cellular inflammatory responses and oxidative stress
arising from a wide range of pathophysiological conditions [18]. The fact that kn has been
shown to be useful in guarding against oxidative damage and inflammation demonstrates
its potential as an adjuvant in the treatment and prevention of a variety of clinical conditions.
However, up to this point in time, no research has been carried out to determine the
protective impact of Kn against the hepatotoxicity and lymphocyte toxicity that are caused
by CP. Therefore, the purpose of this study was to pull the curtain to unveil the possible
protective effects of Knin CP-induced liver and lymphocyte toxicity that was displayed
at different doses and to investigate the mechanisms that explain these possible effects,
regarding its possible influence on oxidative stress and inflammation.
2. Materials and Methods
2.1. Kits, Chemicals and Antibodies
Kinetin (Kn) was obtained from Sigma-Aldrich (Dorset, Germany). Cisplatin was
purchased from Mylan SAS pharmaceutical company (Saint-Priest, France). Kits for reduced glutathione (GSH) (CAT No. GR2511), Glutathione peroxidase (GPx) (CAT No. GP
2524), Malondialdehyde (MDA) (CAT No. MD2529) and Superoxide dismutase (SOD) were
purchased from Biodiagnostic (Cairo, Egypt). Tumor Necrosis Factor α (TNF- α), AKT and
Caspase-3 polyclonal antibodies were purchased from Santa Cruz Biotechnology (Dallas,
TX, USA). Rat ELISA Kits of TNF- α, CRP and Interleukin 6 (IL-6) were obtained from Elabscience biotechnology (Houston, TX, USA) while rat FAS/CD95 (Factor-Related Apoptosis)
ELISA Kit was purchased from Assay Genie, Ireland (CAT No.: RTFI00768). Histopaque 1077 was purchased from Sigma-Aldrich (Dorset, Germany (CAT No. 10771). Rat ELISA Kit
for pAKT/AKT was purchased from Bioassay Technology Laboratory (Shanghai, China).
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2.2. Study Design
All study protocols involving animals were approved by the Institutional Animal
Care and Use Committee at Minia University, Egypt (Permit Number: 54/2019). Adult
male Wistar rats (Animal Care Unit, Faculty of Agriculture, Minia University, weighing
140–160 g) were fed standard laboratory chow (El-Nasr Company, Cairo, Egypt) and water
ad libitum. Rats were accommodated at 22 ◦ C ± 2 ◦ C with humidity of 50% ± 10% with 12
h dark–light cycle. After a 2-week acclimatization period, rats were randomly divided into
9 groups (6 animals each). Control group received only vehicle for 10 days, (0.25 Kn group)
received a dose of 0.25 mg/kg Kn, (0.5 Kn group) received a dose of 0.5 mg/kg Kn and (1.0
Kn group) received a dose of 1.0 mg/kg kinetin. Kn at all different doses was given in a
single daily dose for 10 days, i.p. Kn was freshly prepared in saline as a vehicle (0.9% M/V
NaCl). (CP group): a single intraperitoneal dosage of 7.0 mg/kg cisplatin was administered
on the 4th day of the experiment. (CP + 0.25 Kn group) rats received i.p. 0.25 mg/kgKn
once daily for 10 days along with a single i.p. dose of 7.0 mg/kg cisplatin on the 4th day
of the experiment, (CP + 0.5 Kn group) rats were given 0.5 mg/kg Kn once daily, i.p., for
10 days concomitant with a single i.p. injection of 7.0 mg/kg cisplatin on the 4th day of
the experiment, (CP + 1.0 Kn group) animals received 1.0 mg/kg Kn, i.p., once daily for 10
days concomitant with a single i.p. injection of 7.0 mg/kg cisplatin on the 4th day of the
experiment, and (CP + Vit C group): rats were given 200 mg/kg vitamin C once daily for
10 days orally in addition to a single i.p. injection of 7.0 mg/kg cisplatin on the 4th day
of the experiment. The dose and experimental design of Kn and CP administration were
guided by our previous work [19].
2.3. Serum and Tissue Sample Collection
After ten days (the period of the experiment), rats were anesthetized using diethyl
ether and before sacrificing; blood samples were collected by small capillary tubes from the
retro-orbital plexus, and serum samples were prepared by centrifugation at 3000 rpm for
10 min in a refrigerated centrifuge and stored at −80 ◦ C.
After euthanization by cervical dislocation, liver tissue samples were collected for the
histopathological, biochemical and PCR analyses.
For the histopathological analysis, parts of liver tissues were fixed by 10% formalin,
while for the biochemical and PCR analyses, other parts were frozen with using liquid
nitrogen and stored at −80 ◦ C.
2.4. Lymphocyte Isolation
Lymphocyte isolation was performed as described previously with some modifications [20]. In brief, 7 mL of blood from several groups of rats was applied as a layer
atop Histopaque-1077 (1:1). The layers were separated by centrifugation (400× g) at room
temperature for 30 min, after which mononuclear cells were recovered from the plasma–
Histopaque interface. They were resuspended in lymphocyte medium after being washed
twice with lymphocyte medium (250× g; 1300 rpm; room temperature for 10 min). Lymphocytes were incubated for 24 h with 100 nM Kn and 30 min with 0.6 µM NQO after that,
and various parameters were assessed.
2.5. Biochemical Assays
For the measurement of the levels of ALT, AST, ALP, Alb and bilirubin in serum
samples, commercially available colorimetric assay kits (Sigma-Aldrich) were used, and
the standard procedures were applied.
2.6. Lipid Peroxidation and Antioxidant Status Evaluation
The levels of MDA and GSH as well as GPx and SOD activities were assessed in
the liver homogenates and lymphocytes using commercially available kits (Biodiagnostic,
Cairo, Egypt) following the manufacturer’s instructions.
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2.7. Histopathological Examination
For the histopathological examinations, the previously fixed liver tissues in 10%
formalin were removed, dehydrated in ethanol and prepared as blocks in paraffin wax.
Liver sections 4–5 µm-thick were prepared on clean, dry glass slides, deparaffinized and
stained using hematoxylin and eosin [21]. The sections were then examined and visualized
at 200× magnification using a light microscope (Leika DMRBE, Wetzlar, Germany) to detect
pathological changes.
2.8. Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR)
RiboZol reagent was used for isolating total RNA from the hepatic tissue through a
series of steps. The RNA was quantified using a NanoDrop spectrophotometer, and the
mentioned amount of cDNA was produced using the manufacture protocol of GoTaq®
One-Step RT-qPCR System (Madison, WI, USA). Table 1 depicts the primer sequences. The
results were normalized to Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), which
was used as internal control. The experiments were performed in triplicate.
Table 1. List of primer sequences.
S. No

Sequences (50 -30 )

Gene
Forward

Reverse

1

AKT

GTC GCC TGC CCT TCT ACA AC

CAC ACG ATA CCG GCA AAG AA

2

Caspase-3

GTG GAA CTG ACG ATG ATA TGG C

CGC AAA GTG ACT GGA TGA ACC

3

GAPDH

ACC CAG AAG ACT GTG GAT GG

CAC ATT GGG GGT AGG AAC AC

2.9. Western Blot Analyses
Western blot was performed in accordance with the method previously described [22],
and ready Prep™ buffer for protein extraction (Bio-Rad Inc., catalog #163-2086) was used,
including lysing of the isolated lymphocytes from blood of all experimental animal groups.
Lysates were centrifuged, and protein contents were determined using a Bradford protein
assay kit. Following that, 20 µg of protein from each sample was combined with Laemmli
loading buffer and separated on 10% sodium dodecyl sulfate–polyacrylamide gels. Blotting
of separated protein contents was then performed on nitrocellulose membrane (Millipore, Burlington, MA, USA). Following blocking with 5% skim milk, the membrane was
incubated with primary antibodies against TNF-α and β-actin, followed by secondary
antibodies (HRP-conjugated goat IgG). The proteins were visualized using the enhanced
chemiluminescent kit. The membrane was re-probed with β-actin to demonstrate equivalent loading of the individual sample proteins. Densitometry was performed by Image J 7.0
for semi-quantification of protein bands relative to β-actin, and the results are displayed as
a bar chart.
2.10. Statistical Analysis
Data were expressed as mean ± SEM and statistically analyzed using one-way analysis
of variance (ANOVA) for multiple-group comparisons followed by Tukey–Kramer post hoc
test using GraphPad Prism, version 6 (San Diego, CA, USA), with differences considered
significant at p < 0.01.
3. Results
3.1. Effect on Hepatic Biochemical Parameters
Kinetin (Kn) was given at different doses (0.25, 0.5 and 1 mg/kg) to obtain insights into
the impact of the different doses of Kn treatment on CP-induced hepatotoxicity. All doses
administered to Kn-treated rats displayed non-significant changes in serum ALT, AST,
ALP, albumin and total bilirubin compared to the normal control group. CP significantly
increased levels of ALT, AST, ALP and total bilirubin while markedly decreasing serum
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bilirubin as compared to the normal control group. Remarkably, the lower dose of Kn
(0.25 mg/kg) did not mitigate the level of the abovementioned function parameters except
for in the case of AST levels as compared to the CP group (Figure 1B). However, higher
doses such as 0.5 and 1 mg/kg caused a significant attenuation in the serum level of
the aforementioned parameters in CP-treated rats (Figure 1A–E). The vitamin C group,
which serves as a standard antioxidant, showed a significant improvement in all these
functional markers.

Figure 1. Effect of kinetin on different biochemical parameters. Effect of different doses of Kn and
vitamin C on serum (A) ALT, (B) AST, (C) ALP, (D) albumin and (E) total bilirubin. a Significantly
different from control group, b significantly different from cisplatin group according to one-way
ANOVA followed by Tukey–Kramer multiple comparisons test at p < 0.01, (n = 6). Tests were performed as described in Materials and Methods. ALT: alanine transferase, AST: aspartate transferase,
ALP: alkaline phosphatase, Vit C: vitamin C.

3.2. Effect on Hepatic Redox Status
Cisplatin administration induced oxidative stress in rat liver. It significantly elevated
MDA content while remarkably decreasing GSH content and SOD activity when compared
to the control rats. On the contrary, Kn, at all doses except for the lowest dose (0.25 mg/kg),
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successfully ameliorated the above oxidative stress parameters induced by CP in rat liver
(Figure 2).

Figure 2. Effect Effect of kinetin oon hepatic redox status. Effect of different doses of kinetin and vitamin
C on hepatic (A) MDA, (B) GSH and (C) SOD. a Significantly different from control group, b significantly
different from cisplatin group according to one-way ANOVA followed by Tukey–Kramer multiple
comparisons test at p < 0.01, (n = 6). Tests were performed as described in Research Design and Methods.
MDA: malondialdehyde, GSH: glutathione, SOD: superoxide dismutase, Vit C: vitamin C.

3.3. Effect on TNF-α Level in Liver Homogenates
Hepatic TNF-α concentration was examined as an inflammatory marker that showed
a significant increase in the CP group when compared to the control group. Prior administration of Kn at all doses in addition to Vit C significantly reduced the hepatic TNF-α
concentration compared with the CP group (Figure 3).

Figure 3. Effect Effect of kinetin on hepatic TNF-α level. Effect of different doses of kinetin and
vitamin C on hepatic TNF-α level. a Significantly different from control group, b significantly
different from cisplatin group according to one-way ANOVA followed by Tukey–Kramer multiple
comparisons test at p < 0.01, (n = 6). Tests were performed as described in Research Design and
Methods. TNF-α: Tumor necrosis factor- α, Vit C: vitamin C.

3.4. Effect on Redox Status in Lymphocytes
Oxidative stress markers, such as lipid peroxide content, MDA level, GSH concentration and GPx activity, were assessed for oxidative stress status evaluation in lymphocytes.
Injection with CP caused a remarkable rise in the MDA level as well as a significant decline
in GSH concentration and GPx activity compared with the control (Figure 4A–C). Concomitant treatment of Kn at different doses (0.25, 0.5 and 1.0 mg/kg) or Vit C significantly
restored the GSH level compared to the CP-treated group (Figure 4B). Interestingly, the
highest two doses of Kn in addition to Vit C significantly mitigated oxidative stress in
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the case of MDA levels in comparison with the CP-treated group, whereas a 0.25 mg/kg
Kn dose did not prevent the toxicity induced by CP (Figure 4A). Notably, concomitant
administration of 0.25 and 0.5 mg/kg Kn doses or Vit C did not significantly restore the
GPx activity when compared to the CP group, while in contrast, only the 1 mg/kg Kn
significantly attenuated the remarkable reduction in GPx activity induced in CP-treated
animals (Figure 4C).

Figure 4. Effect Effect of kinetin on redox status in lymphocytes. Effect of different doses of kinetin
and vitamin C on (A) MDA, (B) GSH and (C) GPx in lymphocytes. a Significantly different from
control group, b significantly different from cisplatin group according to one-way ANOVA followed
by Tukey–Kramer multiple comparisons test at p < 0.01, (n = 6). Tests were performed as described
in Research Design and Methods. MDA: malondialdehyde, GSH: glutathione, GPx: Glutathione
peroxidase, Vit C: vitamin C.

3.5. Effect on Inflammatory Status in Lymphocytes
Cisplatin induces inflammation, which is a crucial pathway in its toxicity. Therefore, we tested levels of CRP, IL6, CD95 and TNF-α protein expression as inflammatory
biomarkers. A significant elevation in CRP, IL6, CD95 and TNF-α protein levels was observed in the CP-treated group compared to the control group (Figure 5). Intriguingly,
Kn administration at doses of 0.25, 0.5 and 1.0 mg/kg or Vit C along with CP caused
a significant decrease in CRP, IL6 and CD95 levels as well as downregulation of TNF-α
protein expression (Figure 5D,E) as compared to the CP group.
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Figure 5. Effect Effect of kinetin on inflammatory status in isolated lymphocytes. Effect of different
doses of kinetin and vitamin C on (A) CRP, (B) IL6 and (C) CD95. (D) Western blot analysis showing
effect of different doses of kinetin and vitamin C using TNF-α Ab together with β-actin Ab as an internal
control showing strong activation of TNF-α in CP-treated group (n = 6). (E) Quantitative analysis (fold
changes) of Western blots. a Significantly different from control group, b significantly different from
cisplatin group according to one-way ANOVA followed by Tukey–Kramer multiple comparisons test at
p < 0.01, (n = 6). Tests were performed as described in Research Design and Methods. CRP: C-reactive
protein, IL6: interleukin 6, CD95: cluster of differentiation, Vit C: vitamin C.

3.6. Effect on Hepatic Histological Features
In Figure 6, normal rats injected with Kn at all doses displayed normal architecture
with mild dilated central veins cv in the center of the hepatic lobule with hepatocytes
peripherally arranged, as shown by the arrow, and separated by sinusoids (arrow head)
compared to the normal control group. On the other hand, hepatic sections of the CPtreated group showed marked dilation and congestion of the central veins cv in the center
of the hepatic lobule with hepatocyte degeneration near the central vein, were peripherally
arranged, with a vacuolated to clear cytoplasm, and separated by dilated and congested
sinusoids (arrow head). Concomitant administration of Kn in 0.25 and 0.5 mg/kg doses
and Vit C treatment for CP-injected rats restored the normal architecture of hepatocytes
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with mild congestion in central veins cv in the center of the hepatic lobule with hepatocytes
peripherally arranged (arrow) and separated by sinusoids (arrow head). Intriguingly, the
highest Kn dose (1.0 mg/kg) restored the normal architecture of hepatocytes in hepatic
histopathological sections when compared to the CP-treated group.

Figure 6. Photomicrographs of rats’ livers (H & E × 200). (A) Normal control rat sections showed
normal architecture with normal central veins cv in the center of hepatic lobule with hepatocytes
peripherally arranged, as shown by arrows. (B–D) Normal rats injected with Kn at different doses
(0.25, 0.5 and 1.0 mg/kg, respectively) displayed normal architecture with mild dilated central veins
in the center of hepatic lobule with hepatocytes peripherally arranged, as shown by the arrows, and
separated by sinusoids (arrow head). (E) Hepatic sections of CP (7.0 mg/kg)-treated group showed
marked dilation and congestion of the central veins in the center of hepatic lobule with hepatocyte
degeneration near central vein and were peripherally arranged with a vacuolated to clear cytoplasm,
and separated by dilated and congested sinusoids (arrow head). (F,G) Combination of cisplatin with
Kn (0.25 and 0.5 mg/kg) restored the normal architecture of hepatocytes with mild congestion in
central veins in the center of hepatic lobule with hepatocytes peripherally arranged (arrow) and
separated by sinusoids (arrow head). (H) The highest Kn dose (1.0 mg/kg) restored the normal
architecture of hepatocytes. (I) Combination of cisplatin with 200 mg/kg vitamin C restored the
normal architecture of hepatocytes with mild congestion in central veins in the center of hepatic
lobule with hepatocytes peripherally arranged (arrow) and separated by sinusoids (arrow head), (H
& E × 200).

3.7. Effect on Hepatic AKT, Caspase-3 Gene Expression and pAKT/AKT Ratio
A significant decrease in AKT expression and a marked increase in caspase-3 expression in addition to the pAKT/AKT ratio, as apoptotic markers, were found in the liver
of CP-injected animals in comparison with normal rats, as shown by PCR and ELISA
analyses, respectively. Treatment with Kn at all doses as well as Vit C prior to CP injection
caused a marked rise in the expression of the AKT gene, whereas a remarkable decline was
observed in caspase-3 gene expression as well as the pAKT/AKT ratio when compared
with the CP-injected rats. No marked changes in AKT, caspase-3 gene expressions or the
pAKT/AKT ratio were found in the Kn-injected groups at any of the doses in comparison
with normal animals (Figure 7A–C).
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Figure 7. Effect Effect of kinetin on hepatic AKT, Caspase-3 gene expression and pAKT/AKT ratio.
Effect of different doses of kinetin and vitamin C on (A) AKT gene expression, (B) PAKT/AKT
ratio and (C) Caspase-3 gene expression. a Significantly different from control group, b significantly
different from cisplatin group according to one-way ANOVA followed by Tukey–Kramer multiple
comparisons test at p < 0.01, (n = 6). Vit C: vitamin C.

4. Discussion
In 2016, our research team published a study in which we demonstrated that Kn had
both an antioxidant and an antigenotoxic impact on a variety of mammalian cell lines
representing various organs. In addition, we emphasized that CKs might have multiple
activities depending on the dose that was administered [18], and another study confirmed
our findings by demonstrating that antioxidant activity is a mechanism for the antigenotoxic impact of Kn [23]. Moreover, Kn was demonstrated to have the highest antioxidant
activity up to a concentration of 1 µM among four CKs chosen by Bizzalori [24]. Our first
study was followed by another study which discussed the safety of the systemic use of
Kn [18]. Accordingly, in the present work, we investigated the protective effect of Kn at
different doses against CP-induced toxicity in the liver as well as isolated lymphocytes. To
the best of our knowledge, this is the first report exploring the possible molecular protective mechanisms of Kn concerning its antioxidant, anti-inflammatory and anti-apoptotic
properties against CP-induced hepatotoxicity and lymphotoxicity, which have not been
previously studied.
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Cisplatin is one of the most potent cytotoxic anticancer medicines; nonetheless, hepatotoxicity and lymphotoxicity are two of its significant adverse effects, which represent
a major hurdle limiting its usage. Furthermore, they have been linked to the excessive
generation of ROS and cell and DNA damage [25]. Furthermore, oxidative stress causes
inflammation and the generation of cytokines such as TNF-a and IL-6.
In this context, our study demonstrated that CP treatment resulted in a severe array of
events of hepatotoxicity as evidenced by significant elevation of ALT, AST, ALP and total
bilirubin while a marked hypoalbuminemia was accompanied by distorted architecture
and severe degenerative changes in the hepatocytes. The potential of CP to increase serum
ALT, AST and ALP activity is thought to be a secondary event after CP-induced liver
injury and the subsequent leakage of these enzymes from hepatocytes [26]. Conjointly,
elevated bilirubin levels may be caused by either decreased hepatic bilirubin uptake or
a decreased rate of bilirubin conjugation in the liver [27]. In agreement of our results,
Okoko and Ndoni (2018) reported an elevation in the serum ALT, AST and ALP activities
in CP-induced hepatotoxicity [28]. Notably, the remarkable hypoalbuminemia reported
with CP injection in our study was the same as previously reported by Neamatallah et al.,
(2018) [2]. Interestingly, concomitant treatment with Kn, however, restored the normal
architecture of hepatocytes as well as the aforementioned functional parameters of the liver.
Excess ROS generation in CP-treated rats resulted in an imbalance in oxidant–antioxidant
levels, which lowered scavenging capability toward ROS and promoted oxidative stress. This
was emphasized in our results by the elevation in both hepatic and lymphocyte MDA content,
along with a diminution of the enzymatic antioxidants, including hepatic SOD as well as
GPx, in lymphocytes. Moreover, the depletion of GSH levels in CP-induced rats made the
hepatic tissue as well as lymphocytes more susceptible to oxidative stress. This is similar to
the results obtained by Bentli et al., (2013) [29], Omar et al., (2016a) [7]; Omar et al., (2016b) [30]
and Yadav et al., (2019) [31]. Importantly, in the current study, administration of Kn along
with CP showed protection against oxidative stress compared to the CP group. The potential
protection of Kn against lipid peroxidation and depletion of antioxidant enzymes may reveal
a plausible mechanism of kinetin’s antioxidative action. Olsen et al., (1999) showed how Kn
protects DNA from oxidative damage by preventing ROS generation and scavenging them
before their reaction with the DNA [32].
Our findings are consistent with prior research that found Kn to be effective in lowering
MDA levels and increasing antioxidant enzymes in spermatozoa and other mammalian
cells [28,29]. Additionally, in another study using mouse models, Kn had the ability
to enhance the antioxidant system of the cell by increasing the activities of SOD, GSHpx and heme oxygenase 1 (HO-1), where oxidative damage was induced by aluminum
chloride and D-galactose [33]. Interestingly, we noticed that Kn had intrinsic antioxidant
activity when administered alone and acted as antioxidant upon treatment in combination
with CP in a dose-dependent manner. In this regard, the highest concentration of Kn
(1.0 mg/kg) showed the highest antioxidant potential among all the doses, and this effect
was comparable to or even greater than the effect of the potent antioxidant vitamin C.
Accordingly, we observed that CP-treated rats, which were administered the dose of
1.0 mg/kg kinetin, showed the highest recovery of the functional markers when compared
with the other doses of Kn. Similarly, Abdel-latif et al., (2022) showed that Kn provided
protection against oxidative-stress-induced testicular damage in CP-treated rats, again in a
dose-dependent manner [19].
Different studies reported that CP-induced oxidative stress enhances the process of
inflammation and TNF-α production, which leads to the activation of a large network of
pro-inflammatory cytokines such as IL-1β and IL-6 [2,34,35].
During hepatotoxic damage, pro-inflammatory cytokines such as TNF-, IL-1 β and
IL-6 are released into the circulation by the liver [36]. In the current investigation, hepatic
oxidative stress induced by a single dosage of CP (7.0 mg/kg) was predicted to promote
inflammation as assessed by substantial TNF-α upregulation in both hepatic tissue and
lymphocytes in addition to the remarkable elevation observed in CRP and IL-6 levels,
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which are inflammatory markers, in lymphocytes, which are significantly mitigated by
concomitant administration of different Kn doses. The profound increase in hepatic TNF-α
expression accompanied by CP injection was already detailed in previous studies [3,30].
CD95 (sometimes referred to as Fas) is a member of the tumor necrosis factor receptor
(TNFR) superfamily [37]. Immature dendritic cells (DCs) undergo maturation upon CD95
activation, which increases the expression of MHC class II and DC-lysosome-associated
membrane proteins (LAMPs) and triggers the release of pro-inflammatory cytokines, including IL-1b and TNF-α [38]. Moreover, CP induces plasmalemmal destabilization and
increases membrane fluidity, which causes the death receptor CD95/Fas activation; such
changes activate the extrinsic pathway of apoptosis and contribute to cell death [39]. Likewise, CP significantly elevated CD95 in isolated lymphocytes in our study, emphasizing
its crucial role in both inflammation and apoptosis, and this observation is in concordance
with previous reports [40,41]. Intriguingly, Kn attenuated CD95 levels remarkably at all
doses, indicating its anti-inflammatory and anti-apoptotic properties.
Cisplatin intoxication shifts the balance between pro-and anti-apoptotic signals towards proapoptotic cascade [42]. TNF- is a protein that is involved in inflammatory
responses and is intimately linked to apoptosis [43]. Since the interaction between oxidative stress and inflammation is a hallmark of cell death [44], oxidative stress caused by
CP, which is believed to be via activation of the NF-kB pathway, resulted in inflammation
and apoptosis [2]. In addition, when cells experience apoptosis, caspases 8 and 9 become
activated, which are initiator caspases, resulting in activation of executioner caspases,
including caspases 3 and 7 [45]. Furthermore, executioner caspase-3 activates cellular
proteins and DNA fragmentation factors, resulting in apoptosis-mediated alterations [46].
AKT/PKB is a serine/threonine kinase that belongs to a protein family that also contains
AKT1, AKT2 and AKT3. Cell proliferation, differentiation, apoptosis and cancer are all
regulated by the AKT pathway [47,48]. Of note, it has been reported that the activation of
AKT promotes cell survival, whereas inhibition of AKT activity promotes apoptosis in a
variety of cancer cells [49].
Therefore, in the current work, it was predicted that hepatic oxidative stress brought
on by a single dose of CP (7.0 mg/kg) would result in apoptosis, which was supported by
hepatic AKT downregulation, pAKT/AKT ratio elevation and enhanced caspase-3 gene
expression in rat liver tissue.
Our findings concur with those of Hassan et al., (2020) and Neamatallah et al., (2018),
which demonstrate that CP treatment causes apoptosis in cells [2,3], as well as Dong Li
et al., (2019), who reported that the level of p-Akt protein expression was also found to be
significantly elevated when induced by oxidative stress in chondrocyte apoptosis [50].
Intriguingly, Kn, in the present study, decreased the CP-induced elevation in caspase-3
expression and significantly restored the pAKT/AKT ratio and AKT gene expression in a
dose-dependent manner. Since increased ROS and pro-inflammatory cytokines have been
documented to produce hepatocyte apoptosis and cell death [25,31,51,52], the decreased
expression of caspase-3, pAKT/AKT ratio restoration and AKT gene upregulation in
response to Kn treatment may be secondary to its antioxidant and anti-inflammatory
activities. Our research clearly demonstrated that Kn provided protection against the
liver and lymphocyte damage caused by cisplatin. We were able to directly attribute this
cytokinin anti-apoptotic effect to AKT signaling, identifying it for the first time in the
literature.
This strongly suggests that Kn might directly activate anti-apoptotic signaling at the
cellular level, which is why we think it is significant.
We believe that the current research on receptor-mediated activity may play a significant additive role in elucidating the other robust tissue protection mechanisms of Kn that
have been previously hypothesized or described.
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5. Conclusions
In summary, Kn treatment mitigated the oxidative stress status and inflammation in
the rats. Oxidative stress parameters as well as TNF-α in both livers and lymphocytes were
strongly attenuated by Kn in this animal model of cisplatin-induced hepatotoxicity and lymphotoxicity. Moreover, the anti-apoptotic effects of Kn were accompanied by suppression of
AKT and Caspase-3 expression in livers as well as CD95 in lymphocytes of cisplatin-treated
rats. Our data suggest that Kn protects rat livers and lymphocytes against cisplatin-induced
toxicity through antioxidant, anti-inflammatory and anti-apoptotic mechanisms. Therefore,
we conclude that our results further imply that administration of Kn slows down the
progression of hepatotoxicity as well as lymphotoxicity by inhibiting oxidative damage,
inflammation and apoptosis.
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